Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.
Talquetamab in relapsed/refractory multiple myeloma: Extended follow-up from MonumenTAL-1 and interventions for GPRC5D-related toxicities
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
Adding Atezolizumab to Chemoradiation Increases QOL in SCLC
Addressing Every “Slice of the Pie” in Supportive Oncology Care
Intraoral Photobiomodulation Device Safe, Reduces Oral Mucositis in HNC
Fixed-Duration Mosunetuzumab/Polatuzumab Active in R/R MCL